Eton Pharmaceuticals (ETON) Set to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Eton Pharmaceuticals to post earnings of ($0.02) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The business had revenue of $7.31 million for the quarter, compared to analysts’ expectations of $7.70 million. Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $3.72 on Wednesday. The stock has a market cap of $95.57 million, a PE ratio of -124.00 and a beta of 1.19. Eton Pharmaceuticals has a fifty-two week low of $2.42 and a fifty-two week high of $5.81. The firm’s 50-day simple moving average is $3.75 and its two-hundred day simple moving average is $4.07.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of Eton Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $8.00 price target for the company.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.